



ABOLOGIX awarded a two year Innosuisse Innovation project in collaboration with the University Hospital of Geneva

- **Substantial non-dilutive financial support received for this partnership**
- **Two scientists will be recruited at the University Hospital of Geneva to work on the company's project**

Geneva, Switzerland, July 24, 2020.

Abologix has been granted a 2 year Innosuisse Innovation project in collaboration with the University Hospital of Geneva (HUG). The HUG will be the research partner and Abologix the implementation partner.

The collaboration plans to study the mechanism of action involved in arresting tumour growth through the selective blocking of Junction Adhesion Molecule **JAM-C** by monoclonal antibodies supplied by Abologix. These studies will lead to a deeper understanding of the molecular mechanisms of **JAM-C** blockage to inhibit growth and metastasis of certain lymphomas.

About Abologix

Abologix is a pre-clinical stage biopharmaceutical company developing best-in-class monoclonal antibodies by blocking the Junction Adhesion Molecule **JAM-C** and the extracellular matrix-related protein **Olfactomedin-like protein 3 (Olfml3)** for the treatment of hematological and solid cancers. The company is based in Geneva (Switzerland) and it is a spin-out from the laboratories of Profs. Beat Imhof and Thomas Matthes at the University of Geneva and the Hôpitaux Universitaires de Genève.

Contact Information

Ignacio Faus, Chairman of the Board
Abologix. Sàrl
ignaciofaus@abologix.com